A Phase 1 interventional study of BMS-663068 and Darunavir (DRV) in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Completed. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-08-08.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine if there is an interaction in healthy subjects taking BMS-663068 with Darunavir/Ritonavir and/or Etravirine.
Brief title: drug-drug interaction (DDI)
Primary Purpose: Other : Phase 1 Clinical Pharmacology drug interaction study in healthy subjects
2,094 studies on the registry are indexed under Infections; 364 are open to participants now.
This study's enrollment of 42 is below the median of 113 across 1,305 interventional studies indexed under Infections.
Browse Infections studies →ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet DRV 600mg / RTV 100mg orally orally twice daily on days 7-16
Drug: BMS-663068 · Drug: Darunavir (DRV) · Drug: Ritonavir (RTV)
Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet ETR 200mg orally orally twice daily on days 7-16
Drug: BMS-663068 · Drug: Etravirine (ETR)
Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet DRV 600mg / RTV 100mg and ETR 200mg orally orally twice daily on days 7-16
Drug: BMS-663068 · Drug: Darunavir (DRV) · Drug: Ritonavir (RTV) · Drug: Etravirine (ETR)
BMS-663068
Darunavir (DRV)
Also known as: Prezista
Ritonavir (RTV)
Also known as: Norvir
Etravirine (ETR)
Also known as: Intelence
Maximum observed plasma concentration (Cmax) of BMS-626529
Time frame: 20 timepoints up to day 26
Area under the concentration-time curve in 1 dosing interval (AUC(TAU)) of BMS-626529
Time frame: 20 timepoints up to day 26
Time of maximum observed plasma concentration (Tmax) for BMS-626529, DRV, RTV, and ETR
Time frame: Up to day 26 (20 timepoints for BMS-626529, 24 timepoints for DRV, RTV and ETR)
Concentration at 12 hours (C12) for BMS-626529, DRV, RTV, and ETR
Time frame: Up to day 26 (20 timepoints for BMS-626529, 24 timepoints for DRV, RTV and ETR)
Trough observed plasma concentration (Ctrough) for BMS-626529, DRV, RTV, and ETR
Time frame: Up to day 26 (20 timepoints for BMS-626529, 24 timepoints for DRV, RTV and ETR)
Cmax for DRV, RTV, and ETR
Time frame: 24 timepoints up to 26 day
AUC(TAU) for DRV, RTV, and ETR
Time frame: 24 timepoints up to 26 day
Safety and tolerability endpoints include incidence of adverse event (AEs), serious adverse event (SAEs), AEs leading to discontinuation, deaths, marked laboratory abnormalities, and abnormalities in vital signs, physical examination, and 12-lead ECGs
Time frame: Up to day 27
No study locations are listed for this record.
The record gives a start of Feb 2014, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fostemsavir · Darunavir · Ritonavir · Etravirine